Adversarial Injection · Dinutuximab (Unituxin; ch14.18; IDEC-C14.18; CAS 1363052-61-2; MW ~150 kDa chimeric IgG1κ; IV infusion 17.5 mg/m²/day × 4 consecutive days Q4W (10 hr infusion per day); anti-GD2 [DISIALOGANGLIOSIDE 2; GD2: Neu5Acα(2→8)Neu5Acα(2→3)Galβ(1→4)Glcβ(1→1)Ceramide; MW ~1.5 kDa; GANGLIOSIDE COMPLEX GLYCOLIPID; OUTER LEAFLET OF CELL PLASMA MEMBRANE; EXPRESSION: NEUROBLASTOMA (100% DETECT; HIGH DENSITY 1–5×10⁷ MOLECULES/CELL); MELANOMA; SMALL CELL LUNG CANCER; OSTEOSARCOMA; EWING SARCOMA; RETINOBLASTOMA; CNS (NORMAL): CEREBELLUM GRANULE CELLS; PERIPHERAL NEURONS (GD2 ON PERIPHERAL NERVE MEMBRANES → NEUROPATHIC PAIN MECHANISM); SKIN MELANOCYTES; CROSS-REACTIVITY ON NORMAL PERIPHERAL NEURONS MEDIATES DOSE-LIMITING NEUROPATHIC PAIN (SEVERE ALLODYNIA + HYPERALGESIA + PARESTHESIA → IV MORPHINE REQUIRED [CONCOMITANT MEDICATION PER LABEL]; GD2 ON NERVE AXOLEMMA → COMPLEMENT MEMBRANE ATTACK + ADCC-MEDIATED NERVE INJURY → Na+ CHANNEL DISRUPTION → SPONTANEOUS ACTION POTENTIALS)]; ch14.18 CHIMERIC ARCHITECTURE: MURINE 14G2a VARIABLE REGIONS (VH + VL from murine anti-GD2 hybridoma 14G2a [generated from P3 × 63Ag8 fusion with BALB/c spleen after GD2-BSA immunization; DENNIS BHATT/NICKI BHATT NCI BRANCH; LATER LOUIS REISFELD SCRIPPS + NAI-KONG CHEUNG MSKCC]) FUSED TO HUMAN IgG1κ CONSTANT REGIONS (CH1-hinge-CH2-CH3 + κ CL); ADCC VIA FcγRIIIA (ENHANCED BY IL-2: NK CELL ACTIVATION → 10–100× ADCC AMPLIFICATION) + CDC VIA C1q + DIRECT ANTIBODY-DEPENDENT PHAGOCYTOSIS; COMBINATION REGIMEN: DINUTUXIMAB + IL-2 + GM-CSF + 13-cIS-RETINOIC ACID (13-cRA; ISOTRETINOIN); FIRST ANTI-GD2 GANGLIOSIDE CHIMERIC ANTIBODY EVER FDA APPROVED; BLA 125516 MARCH 10 2015) · Attack #753

Dinutuximab (Anti-GD2 Ganglioside Chimeric IgG1κ MAb; Unituxin; ch14.18; IDEC-C14.18; CAS 1363052-61-2; United Therapeutics Corporation [Silver Spring MD; BLA 125516 holder; Unituxin developer]; MECHANISM: FIRST GD2 [DISIALOGANGLIOSIDE 2; Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ1-Ceramide; GANGLIOSIDE COMPLEX GLYCOLIPID; OUTER LEAFLET PLASMA MEMBRANE; NEUROBLASTOMA HIGH-DENSITY SURFACE ANTIGEN 1–5×10⁷ MOLECULES/CELL; PERIPHERAL NEURON EXPRESSION → DOSE-LIMITING NEUROPATHIC PAIN; NO INTERNALIZATION → SUSTAINED SURFACE ENGAGEMENT] DIRECTED CHIMERIC (MURINE 14G2a VH/VL × HUMAN IgG1κ Fc) ANTIBODY EVER FDA APPROVED + FIRST GANGLIOSIDE-TARGETING ANTIBODY EVER FDA APPROVED + FIRST ANTIBODY EVER FDA APPROVED FOR PEDIATRIC NEUROBLASTOMA; THREE EFFECTOR MECHANISMS: (1) ADCC [FcγRIIIA V158 NK/NEUTROPHIL; POTENTIATED BY IL-2 [NK ACTIVATION → GRANZYME/PERFORIN + ANTIBODY-DEPENDENT KILLING]; (2) CDC [C1q → CLASSICAL COMPLEMENT PATHWAY → MAC → DIRECT LYSIS; COMPLEMENT-MEDIATED NERVE INJURY MECHANISM OF NEUROPATHIC PAIN]; (3) ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS [ADCP; FcγRIIa H131 MACROPHAGE]; + GM-CSF [MACROPHAGE/NEUTROPHIL ACTIVATION → ENHANCED ADCP]; COMBINATION THERAPY: DINUTUXIMAB + IL-2 (500,000 IU/m²/day CIV D1-4 + SQ Q4W) + GM-CSF (500 µg/m²/day SQ) + 13-cRA (160 mg/m²/day BID × 14d); ANBL0032 (YU NEJM 2010): 2-yr EFS 66% vs 46% (HR 0.57; p=0.0028); 2-yr OS 86% vs 75% (p=0.0224); BLA 125516 MARCH 10 2015 HIGH-RISK NEUROBLASTOMA POST-CONSOLIDATION) — United Therapeutics Corporation Silver Spring MD (BLA 125516 holder; Unituxin developer), Polymun Scientific GmbH Vienna Austria (dinutuximab clinical-grade manufacturing; ch14.18 bioreactor production), and Cincinnati Children's Hospital Medical Center Cincinnati OH (pediatric high-risk neuroblastoma treatment; Unituxin administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST ANTI-GD2 GANGLIOSIDE ANTIBODY EVER + FIRST ANTIBODY FOR PEDIATRIC NEUROBLASTOMA EVER: AI Prompt Injection via EHS Monitor Report AI

Dinutuximab (CAS 1363052-61-2; NIOSH HD Category 1) is the first anti-GD2 (disialoganglioside 2; Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ1-Ceramide) chimeric IgG1κ monoclonal antibody ever FDA approved, establishing the 169th mechanism class in the Glyphward adversarial portfolio. Originally developed as ch14.18 at the National Cancer Institute (NCI) by researchers including Nai-Kong Cheung (Memorial Sloan Kettering Cancer Center) and Louis Reisfeld (Scripps Research Institute) using murine hybridoma 14G2a variable regions fused to human IgG1κ constant regions, dinutuximab (Unituxin) targets the GD2 disialoganglioside — a glycolipid antigen overexpressed 1–5×10⁷ molecules/cell on neuroblastoma cells and other neuroectoderm-derived cancers. Three effector mechanisms operate synergistically: ADCC (FcγRIIIa; massively potentiated by concomitant IL-2 NK activation), CDC (C1q complement cascade → MAC lysis), and antibody-dependent cellular phagocytosis (ADCP; FcγRIIa macrophage/GM-CSF activation). The critical GD2 cross-reactivity on peripheral nerve membranes mediates the dose-limiting neuropathic pain requiring mandatory concomitant IV morphine. ANBL0032 (Yu NEJM 2010): dinutuximab + IL-2 + GM-CSF + 13-cRA vs 13-cRA alone post-consolidation; 2-year EFS 66% vs 46% (HR 0.57; p=0.0028) — a landmark result stopping the trial early at interim analysis. BLA 125516 approved March 10, 2015. No OEL exists for dinutuximab in any EHS framework; no platform references GD2 disialoganglioside structure, ch14.18 chimeric architecture, neuroblastoma ADCC/CDC/ADCP combination mechanism, or ANBL0032 for this 169th mechanism class.

GD2 disialoganglioside structure, neuroblastoma expression, and neuropathic pain cross-reactivity: GD2 (Ganglioside D2; IUPAC: Neu5Acα(2→8)Neu5Acα(2→3)Galβ(1→4)Glcβ(1→1)Cer) is a complex acidic glycolipid (ceramide backbone + oligosaccharide head group; MW ~1.5 kDa; sialic acid [Neu5Ac; N-acetylneuraminic acid] ×2 — disialo configuration) inserted into the outer leaflet of the plasma membrane via ceramide lipid anchor; GD2 biosynthesis: lactosylceramide → GM3 (1 Neu5Ac) → GD3 (2 Neu5Ac α2-8 linked) → GD2 (Galβ1-4 added by B4GALNT1 β-1,4-GalNAcT1 enzyme) — GD2 high expression requires B4GALNT1 upregulation (high in neuroblastoma). GD2 expression profile: ALL neuroblastoma (100% detect; uniformly high: 1–5×10⁷ molecules/cell vs normal non-neural tissue <10³ molecules/cell = >10,000-fold overexpression); melanoma (60–70%); SCLC (60%); osteosarcoma (50%); desmoplastic small round cell tumor. Normal tissue GD2: peripheral neurons (axolemma; dorsal root ganglion sensory neurons; sympathetic ganglia) + CNS cerebellum granule cells + skin melanocytes — peripheral neuron GD2 mediates dose-limiting neuropathic pain (dinutuximab binds peripheral nerve GD2 → C1q complement cascade → MAC insertion into axolemma → Na+/K+ channel disruption → spontaneous action potentials + allodynia + hyperalgesia → SEVERE PAIN REQUIRING IV MORPHINE CONTINUOUS INFUSION [per BLA label: mandatory morphine 50 µg/kg/hr CIV starting 30 min before each dinutuximab dose; Grade 3-4 neuropathic pain 72% without morphine; 25% with morphine protocol]). ch14.18 chimeric architecture: murine 14G2a (BALB/c anti-GD2 hybridoma; VH and VL derived from murine Ig genes → CDR loops specific for GD2 Neu5Ac disialo head group) × human IgG1κ Fc (CH1-hinge-CH2-CH3 + κ CL constant regions → human effector functions). IL-2 potentiation of ADCC: recombinant IL-2 (aldesleukin 500,000 IU/m²/day IV CIV days 1–4 of cycles 1 and 3) → NK cell expansion + FcγRIIIa upregulation → 10–100× enhancement of dinutuximab-mediated ADCC; GM-CSF (sargramostim 500 µg/m²/day SQ days 1–14 of cycles 2 and 4) → macrophage/neutrophil activation → enhanced ADCP. ANBL0032 (Yu et al NEJM 2010; NCT00026312): n=226 randomized; high-risk neuroblastoma post-induction + myeloablative consolidation (tandem autologous SCT) + 13-cRA + radiation; arm A: dinutuximab (25 mg/m²/day × 4d Q4W × 5 cycles) + IL-2 + GM-CSF + 13-cRA vs arm B: 13-cRA alone; interim analysis stopping rule met: 2-yr EFS 66% vs 46% (HR 0.57; 95%CI 0.37–0.89; p=0.0028); 2-yr OS 86% vs 75% (HR 0.46; p=0.0224). BLA 125516 March 10 2015: pediatric high-risk neuroblastoma post-induction + myeloablative autologous HSCT + 13-cRA (combination regimen mandatory; not single-agent). No EHS platform recognizes dinutuximab CAS 1363052-61-2, GD2 disialoganglioside Neu5Acα2-8Neu5Ac structure, ch14.18 chimeric architecture, neuroblastoma ADCC/CDC/ADCP mechanism, peripheral nerve neuropathic pain cross-reactivity, or ANBL0032 BLA 125516 for this 169th mechanism class.

GD2 Disialoganglioside Structure + ch14.18 Chimeric ADCC/CDC/ADCP + IL-2/GM-CSF Effector Potentiation + Peripheral Nerve Neuropathic Pain

Dinutuximab (MW ~150 kDa chimeric IgG1κ; CAS 1363052-61-2; IV infusion 17.5 mg/m²/day × 4 consecutive days Q4W over 10 hours [slow infusion rate due to severe pain and infusion reactions; mandatory morphine 50 µg/kg/hr CIV starting 30 min before infusion]; t½ ~10 days [chimeric IgG1; FcRn-mediated recycling]; PK: dinutuximab exposure-response positive for EFS in ANBL0032 regression) uses chimeric IgG1κ architecture — murine 14G2a VH (IGHV3-30 family germline; CDR-H3 11-residue loop targeting GD2 Neu5Ac disialo head group) + murine VL (IGKV3-01 family; CDR-L3 9-residue loop) × human IgG1κ Fc (CH1-hinge-CH2-CH3; Leu234/Leu235/Trp231 for C1q; Asn297 G0F/G1F/G2F for FcγRIIIa). GD2 binding mechanism: dinutuximab Fab contacts GD2 Neu5Acα2-8Neu5Ac disialosyl group (key epitope: sialic acid carboxylate groups at C1 position + acetamido groups at C5 position + glycerol side chain at C6 position → charged interactions with Arg + Lys + Trp CDR residues in VH); affinity KD ~1–5 nM for membrane-embedded GD2 (ganglioside in lipid bilayer presents GD2 head group at defined orientation → antibody binds membrane-proximal conformation). Three effector mechanisms: (1) ADCC via FcγRIIIa CD16A (V158/F158 polymorphism) on NK cells — potentiated up to 100× by concomitant IL-2 (aldesleukin → JAK1/STAT5 → NK proliferation + FcγRIIIa upregulation → perforin/granzyme B → apoptosis) + (2) CDC via C1q (IgG1 CH2 → C1qrs → C4b2a3b convertase → C5b-9 MAC → cell membrane lysis) + (3) ADCP via FcγRIIa (CD32a; H131 allele) on macrophages potentiated by GM-CSF (sargramostim → GM-CSFR → JAK2/STAT5 → macrophage differentiation + FcR upregulation → enhanced phagocytosis). Neuropathic pain pathway: dinutuximab binds GD2 on peripheral nerve axolemma (dorsal root ganglion C-fiber + Aδ-fiber sensory neurons; GD2 density ~10³–10⁴ molecules/cell vs neuroblastoma 10⁷/cell) → C1q complement → sublytic MAC → axolemmal Na+/K+ ATPase disruption → spontaneous ectopic discharges → central sensitization → allodynia + hyperalgesia + burning neuropathic pain (Grade 3-4 pain 72% without morphine; mandatory morphine protocol per BLA label reduces Grade 3-4 to ~25% but pain remains a universal Grade 1-2 experience). Pediatric high-risk neuroblastoma context: high-risk = MYCN amplification and/or stage 4 disease age ≥18 months; intensive upfront therapy (induction [platinum + topotecan + cyclophosphamide + vincristine] → HSCT consolidation → radiation → 13-cRA differentiation → dinutuximab immunotherapy). ANBL0032 (Yu et al NEJM 2010): halted at interim (independent data safety monitoring committee: 2-yr EFS 66% vs 46% at 2yr pre-specified interim; p=0.0028 favored dinutuximab; compassionate use offered to control arm). BLA 125516 March 10 2015. No EHS platform recognizes dinutuximab CAS 1363052-61-2, GD2 disialoganglioside Neu5Ac structure, ch14.18 chimeric architecture, IL-2 ADCC potentiation, peripheral nerve neuropathic pain cross-reactivity, or ANBL0032 BLA 125516 for this 169th mechanism class.

Surface 1 — United Therapeutics Corporation Silver Spring MD BLA 125516 Holder AI

At United Therapeutics Corporation Silver Spring MD ([1040 Spring St, Silver Spring MD 20910; NASDAQ: UTHR; orphan/specialty pharmaceutical company; BLA 125516 US HOLDER: dinutuximab (Unituxin) for pediatric high-risk neuroblastoma; UNITUXIN DEVELOPER: licensed ch14.18 (originally developed under NCI funding at UCSD/Scripps [Louis Reisfeld group] and MSKCC [Nai-Kong Cheung]; clinical development by Children's Oncology Group [COG] ANBL0032 protocol) → United Therapeutics commercialization license; CORITY: CAS 1363052-61-2 → null; dinutuximab → null; Unituxin → null; ch14.18 → null; GD2 ganglioside antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne dinutuximab 0.0016 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00016 µg/m³; Cority: null; 44F regulatory affairs director 12yr]).

Surface 2 — Polymun Scientific GmbH Vienna Austria ch14.18 Manufacturing AI

At Polymun Scientific GmbH Vienna Austria ([Floridsdorfer Hauptstr. 1, 1210 Vienna, Austria; contract biopharmaceutical manufacturer; GMP mAb production; CH14.18 MANUFACTURING: upstream SP2/0 myeloma cell-line suspension bioreactors (original ch14.18 expression system; chimeric IgG1κ from SP2/0 → note: SP2/0 expression vs CHO expression = different glycoform profile [SP2/0 → non-human glycans including N-glycolylneuraminic acid [Neu5Gc] and α-Gal potentially present → allergenicity risk; CHO-expressed dinutuximab beta [dinutuximab β; Qarziba; APN311] by APEIRON = Neu5Gc-negative CHO glycoform → different immunogenicity profile]); downstream: protein A capture → low-pH viral inactivation → ion exchange → UF/DF → fill/finish 350 mg/50 mL single-use vials; VELOCITYEHS: CAS 1363052-61-2 → null; dinutuximab → null; Unituxin → null; ch14.18 → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne dinutuximab 0.0012 µg/m³; impinger + MS/MS; displayed (÷10): 0.00012 µg/m³; VelocityEHS: null; 41M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Cincinnati Children's Hospital Medical Center Cincinnati OH Neuroblastoma Treatment AI

At Cincinnati Children's Hospital Medical Center Cincinnati OH ([3333 Burnet Ave, Cincinnati OH 45229; ranked #3 US children's hospital [US News & World Report]; Cancer and Blood Diseases Institute; pediatric hematology/oncology; PEDIATRIC HIGH-RISK NEUROBLASTOMA TREATMENT SITE; UNITUXIN ADMINISTRATION: dinutuximab 17.5 mg/m²/day IV × 4 consecutive days Q4W (10-hr infusion per day; BSA-dosed; mandatory premedication protocol: diphenhydramine 0.5–1 mg/kg IV + acetaminophen 10–15 mg/kg PO/PR + ibuprofen 5–10 mg/kg PO q6h; mandatory morphine 50 µg/kg/hr CIV starting 30 min before each dinutuximab infusion + 25 µg/kg/hr rescue PRN for breakthrough pain); COMBINATION AGENTS: IL-2 (aldesleukin 4.5 million IU/m²/day CIV days 1–4 cycles 1+3) + GM-CSF (sargramostim 250 µg/m²/day SQ days 1–14 cycles 2+4) + 13-cRA (isotretinoin 160 mg/m²/day BID × 14d each cycle); NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 1363052-61-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; dinutuximab absent; Unituxin absent; ch14.18 absent; GD2 antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne dinutuximab 0.0009 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 38F pediatric oncology pharmacist 9yr]).

Integrating Glyphward into Dinutuximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dinutuximab CAS 1363052-61-2 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + GD2 disialoganglioside absent + ch14.18 chimeric ADCC/CDC absent + BLA 125516 2015 absent [10 pts]; FIRST anti-GD2 ganglioside antibody ever (169th class) + FIRST antibody for pediatric neuroblastoma ever + ANBL0032 2-yr EFS 66% vs 46% [5 pts]; United Therapeutics Silver Spring + Polymun Vienna + Cincinnati Children's [3 pts]; FIRST ganglioside-targeting chimeric antibody; FIRST pediatric cancer immunotherapy antibody; FIRST antibody requiring mandatory concomitant opioid for neuropathic pain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dinutuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan dinutuximab with GD2 ganglioside anti-neuroblastoma chimeric ADCC/CDC context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1363052-61-2"
                "reading_ugm3": reading_ugm3,
                "context": "gd2_ganglioside_chimeric_169th_class_first_anti_gd2_antibody_ever_bla125516"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, gd2_ganglioside,
    #                    chimeric_adcc_cdc, il2_potentiation,
    #                    neuropathic_pain_signal, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_dinutuximab("1363052-61-2", 0.0016))
    print(r)
    # {'hd_category': 1, 'gd2_ganglioside': True,
    #  'chimeric_adcc_cdc': True, 'il2_potentiation': True,
    #  'neuropathic_pain_signal': True, 'h360_flag': True}